Skip to main content

Table 2 Treatment against spasticity.

From: Efficacy of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients with spinal symptoms

 

Before TCA

After TCA

Baclofen

7.56 ± 16.06; 0 – 80 mg, n = 117 without baclofen

6.44 ± 15.51; 0 – 80 mg, n = 125 without baclofen

Tolperison

1.19 ± 8.20; 0 – 75 mg, n = 154 without tolperison

1.34 ± 7.41; 0 – 50 mg, n = 152 without tolperison

Tizanidin

1.94 ± 5.29; 0 – 32 mg, n = 132 without tizanidin

3.38 ± 6.64; 0 – 32 mg, n = 110 without tizanidin

  1. All data are given as mean ± standard deviation; minimum – maximum; n = number of patients; TCA = standardized intrathecal triamcinolon acetonide application according to the methods section.
Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us